Pediatric Anaplastic Embryonal Rhabdomyosarcoma: Targeted Therapy Guided by Genetic Analysis and a Patient-Derived Xenograft Study
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2018 · 1 min read
In brief
In brief
Case report of an 8-year-old with relapsed anaplastic embryonal rhabdomyosarcoma treated with vorinostat based on genomic profiling revealing BCOR, ARID1A, and SETD2 mutations. The HDAC inhibitor produced transient clinical response, with antitumor activity confirmed in a patient-derived xenograft model showing tumor necrosis.
Written by the GCMD Library team from the article.
Statements in this article
Therapy for rhabdomyosarcoma has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the late 1960s.
Identification of molecular alterations through next-generation sequencing of individual tumor specimens has facilitated the use of more targeted therapeutic approaches for various malignancies.
Malignancies common in children have been less amenable to targeted therapies.
Genomic testing of embryonal rhabdomyosarcoma with anaplastic features revealed mutations in BCOR, ARID1A, and SETD2 genes, each of which contributes to epigenetic regulation and interacts with or modifies the activity of histone deacetylases.
The patient was treated with the HDAC inhibitor vorinostat as a single agent based on genomic findings showing mutations affecting histone deacetylase activity.
The tumor responded transiently to vorinostat followed by subsequent disease progression.
The antitumor activity of vorinostat observed with the patient-derived xenograft model reflected clinical observations in that obvious areas of tumor necrosis were evident.